Ligand Pharmaceuticals

SVP of Investments and Head of Clinical Strategy with over 20 years in senior pharma roles including at Pfizer. She previously was President and CMO of AZTherapies and led development programs across multiple therapeutic areas.

SVP of Investments and Business Development at Ligand. He spent over 15 years at HealthCare Royalty Partners handling deal sourcing and structuring across the US and Europe, and earlier was a principal at The Frankel Group.

SVP of Investment Operations and an Investment Committee member at Ligand with decades of healthcare investment experience. He co-founded the healthcare group at Fortress's Drawbridge fund and co-led the healthcare team at Hayfin Capital Management.

VP of Portfolio Strategy and Investments with nearly two decades in life sciences. She founded Hay Advisory Corporation and previously led investment analysis at DRI Capital, a pharmaceutical royalty firm.

VP of Investments and Business Development at Ligand. He was previously Global Team Leader for Healthcare at Third Bridge Group and founder and CIO of Reef Knot Capital, with prior roles at Visium and Highland Capital.

VP of Investments and Business Development with over a decade in life sciences investing. He was a Senior Principal at Gurnet Point Capital and previously worked in investment banking at MTS Health Partners.

VP of Investments and Business Development, previously a Principal at Blackstone Life Sciences leading large-scale investments. He also worked in biopharma M&A at Lazard and in corporate strategy at Moderna and Flagship Pioneering.

Senior Director of Investments and Business Development with experience in commercialization and partnering across therapeutics, diagnostics, and life sciences. He previously led technology transfer at LA BioMed, USC, and the UC system and worked at General Inception.

Ligand's Chief Legal Officer since 2022, previously VP and Special Counsel at the company. He spent over a decade as Chief Legal Officer at HealthCare Royalty Partners and worked on corporate transactions at Willkie Farr & Gallagher.

VP of New Product Development focused on new applications and IP for the Captisol cyclodextrin drug-delivery technology. He joined via the 2011 CyDex acquisition and previously led CMC services at Oread Laboratories.

SVP of Biology and Scientific Affairs, with Ligand since 1994, having led major discovery and development programs. He now leads clinical and scientific due diligence on Ligand's royalty and project finance investments.

Head of People Operations at Ligand since June 2024, leading the company's people strategy. She previously held senior HR leadership roles at BioLineRx, Clarion Healthcare, Oncopeptides, and EMD.

Ligand's CFO, having previously led the company's finance and accounting functions since 2016. He earlier held senior finance and accounting roles at Receptos, Illumina, Intuit, and PwC, and is a California CPA.

SVP of Technical Operations and Quality Assurance overseeing quality and operations for Ligand's Captisol technology business. He joined via the 2011 CyDex acquisition and has extensive pharmaceutical manufacturing experience.